Therefore, understanding the mechanisms behind ICIs’ limited efficacy in EGFR-TKI-resistant NSCLC and exploring strategies to enhance their effectiveness remained key research priorities. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.